Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020

Prolonged symptom duration and disability are common in adults hospitalized with severe coronavirus disease 2019 (COVID-19). Characterizing return to baseline health among outpatients with milder COVID-19 illness is important for understanding the full spectrum of COVID-19-associated illness and tailoring public health messaging, interventions, and policy. During April 15-June 25, 2020, telephone interviews were conducted with a random sample of adults aged ≥18 years who had a first positive reverse transcription-polymerase chain reaction (RT-PCR) test for SARS-CoV-2, the virus that causes COVID-19, at an outpatient visit at one of 14 U.S. academic health care systems in 13 states. Interviews were conducted…

• UD
  U.S. Department of Defense
• UT
  United Therapeutics Corporation
• IR
  Intermountain Research and Medical Foundation
• CP
  Cumberland Pharmaceuticals
• RP
  Regeneron Pharmaceuticals
• MF
  Marcus Foundation
• UO
  University of Oxford
• NI
  National Institutes of Health
• CF
  Centers for Disease Control and Prevention
• JP
  Janssen Pharmaceuticals
• AP
  Actelion Pharmaceuticals